Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Inclusion Criteria: * Histologically confirmed melanoma with stage IV disease * Radiologically confirmed brain metastasis (n \>= 1) with at least one measurable central nervous system (CNS) lesion \>= 10 mm on T1-weighted gadolinium enhanced magnetic resonance imaging (MRI) and unequivocal evidence of progression * No indication for stereotactic radiotherapy * At least 4 weeks from any anticancer treatment (cytotoxic chemotherapy, signal transduction inhibitors, immunotherapy or radiation) * Absolute neutrophil count (ANC) 1 x 10\^9/L * Platelets \> 100,000/L * Hemoglobin (Hgb) \>= 10 g/dL * Creatinine =\< 1.5 x upper limit of normal (ULN) * Albumin \>= 2.5 g/dL * Serum bilirubin \< 1.5 x ULN unless due to Gilbert's syndrome * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x ULN if documented liver metastases or \< 3 X ULN without liver metastasis * \> 18 years old (y/o) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Females of reproductive age must agree to the use of an effective contraceptive method while on treatment, beginning 2 weeks before the first dose of investigational product and for 28 days after the final dose of investigational product for women. Males able to father a child must practice adequate methods of contraception or completely abstain from intercourse from the first dose of investigational treatment until one week after the final dose of investigational treatment * Women of childbearing potential must…